Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Yu

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Chinese Clinical Oncology|June 11, 2024
PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811James Yu, Anwaar Saeed
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal AdenocarcinomaJames Yu, Rutika Mehta
Cureus|January 18, 2021
Bisphosphonate-Induced Acute Orbital Inflammation in a Patient With Underlying Thyroid OphthalmopathyJames Yu, Jian Guan
Journal of Spine Surgery (Hong Kong)|May 8, 2018
Platelet-rich plasma injections: an emerging therapy for chronic discogenic low back painSuja Mohammed, James Yu
Cancer Journal (Sudbury, Mass.)|February 1, 2012
Status quo--standard-of-care medical and radiation therapy for glioblastomaKevin P Becker, James Yu
Acta Dermato-Venereologica|June 25, 2026
Aspects of Adverse Effects of Cosmetic Products: An Invited Narrative ReviewJames Yu, Peter C Schalock
Expert Opinion on Investigational Drugs|January 26, 2024
Progress in the treatment of anal cancer: an overview of the latest investigational drugsJames Yu, Richard D Kim
Journal of Hepatocellular Carcinoma|July 24, 2023
Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic InsightsJames Yu, Robin Park, Richard Kim
Oncotargets and Therapy|November 1, 2021
Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of InfigratinibJames Yu, Amit Mahipal, Richard Kim
Cancers|March 13, 2024
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular CarcinomaAlireza Tojjari, James Yu, Anwaar Saeed
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Chinese Clinical Oncology|June 11, 2024
PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811James Yu, Anwaar Saeed
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal AdenocarcinomaJames Yu, Rutika Mehta
Cureus|January 18, 2021
Bisphosphonate-Induced Acute Orbital Inflammation in a Patient With Underlying Thyroid OphthalmopathyJames Yu, Jian Guan
Journal of Spine Surgery (Hong Kong)|May 8, 2018
Platelet-rich plasma injections: an emerging therapy for chronic discogenic low back painSuja Mohammed, James Yu
Cancer Journal (Sudbury, Mass.)|February 1, 2012
Status quo--standard-of-care medical and radiation therapy for glioblastomaKevin P Becker, James Yu
Acta Dermato-Venereologica|June 25, 2026
Aspects of Adverse Effects of Cosmetic Products: An Invited Narrative ReviewJames Yu, Peter C Schalock
Expert Opinion on Investigational Drugs|January 26, 2024
Progress in the treatment of anal cancer: an overview of the latest investigational drugsJames Yu, Richard D Kim
Journal of Hepatocellular Carcinoma|July 24, 2023
Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic InsightsJames Yu, Robin Park, Richard Kim
Oncotargets and Therapy|November 1, 2021
Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of InfigratinibJames Yu, Amit Mahipal, Richard Kim
Cancers|March 13, 2024
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular CarcinomaAlireza Tojjari, James Yu, Anwaar Saeed
Pageof 15